Eli Lilly and Company (NYSE:LLY), a United States-based pharmaceutical company, announced on Friday the retirement of Philip Johnson from the position of group vice president and treasurer.
Johnson is retiring from the company at the end of February to pursue a new professional opportunity. The successor to Johnson will be revealed at a future date.
Johnson headed the company's investor relations group for 11 years and was consistently named Top Investor Relations Officer by Institutional Investor. He worked as the company's treasurer since 2018 and has headed the firm's efforts within the financial community to drive positive social and economic change for underrepresented groups.
Solvonis Therapeutics appoints Water Tower Research to strengthen US market positioning
Atrium Therapeutics announces inducement grants to seven new employees
GXO appointed to manage NHS England bowel cancer home testing kits
Samsung Biologics honoured at 2026 CDMO Leadership Awards
Frost & Sullivan names Abzena a market-leading ADC CDMO
Vulcan Two signs five-year ERP licence agreement to support ePharmacy expansion
SportsMed Physical Therapy named Physical Therapy Company of the Year
Ensorcell adds new senior leadership team members
GelMEDIX completes USD13m seed financing, announces first partnership
AmacaThera named Life Sciences Ontario Emerging Company of the Year
GenSight Biologics reports first patient treated in GS010 REVISE study
Biophytis secures Asian partnership and investment to advance Phase 3 sarcopenia programme